 ALI occurs through a common pathway of oxidant stress and inflammation, injuring the lungs and rendering them dysfunctional for gas exchange. The alveolar macrophage AM is an important mediator of the inflammatory response, with roles such as phagocytosis and secretion of inflammatory cytokines that are key components of lung injury and repair. While more than one mechanism may explain the previous observations of a decreased incidence of ALI in diabetics, the data in chronic alcoholics suggests that AM dysfunction may play a role in the in the development of ALI leading us to hypothesize that DM may similarly alter the pulmonary microenvironment, thereby decreasing the susceptibility to ALI. Furthermore, early preliminary data suggests that the AM activity of peroxisome proliferator-activated receptor gamma PPARγ, a transcription factor with anti-inflammatory properties, may be increased in diabetics. In addition, evidence suggests that macrophage activation into a pro-inflammatory versus an anti-inflammatory state may be tissue specific and altered by obesity and insulin resistance i.e. compartmentalized in the lung. However, the effect of DM on the pulmonary inflammatory response and specifically AM function is as yet unknown. PPARγ is highly expressed in AMs, and thus PPARγ ligands have direct affects on AMs to influence lung inflammation by inhibiting oxidative burst and enhancing AM phagocytic function. PPARγ and its ligands influence AM differentiation into M1 pro-inflammatory and M2 anti-inflammatory phenotypes and a recent preclinical study demonstrated effective prevention of ALI by pretreatment with a PPARγ ligand. However, the effect that DM and PPARγ ligands have on AM phenotypic differentiation, PPARγ expression, oxidative stress and AM phagocytic function has not been well investigated. To our knowledge, there is no data on AM PPARγ activity in DM, and little is known about how this disease state may alter the pulmonary inflammatory milieu. The investigators hypothesize that DM reduces the risk of ALI by modulating AM differentiation and function via PPARγ expression, oxidative stress and AM phagocytic function, which may be positively influenced by exposure to a PPARγ ligand. Examining the impact of DM and PPARγ on AM phenotype and function may identify mechanisms responsible for the decreased incidence of ALI in diabetics; improve our understanding of the pathogenesis of a common and lethal disease, and lead to novel therapies for both diabetic and non-diabetic critically ill patients 